𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia

✍ Scribed by M. Cecilia Dignani; John H. Rex; Ka-Wah Chan; Gordon Dow; Margarida deMagalhaes-Silverman; AnneMarie Maddox; Thomas Walsh; Elias Anaissie

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
78 KB
Volume
104
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination chemotherapy with low-dose c
Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia
✍ Wang-Gang Zhang; Fang-Xia Wang; Yin-Xia Chen; Xin-Mei Cao; Ai-Li He; Jie Liu; Xi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract As sensitization of leukemic cells with granulocyte colony‐stimulating factor (G‐csf) can enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML), a pilot study was conducted in order to evaluate the effect of G‐csf priming combined with low‐dose chemotherapy in patient

A Phase II study of estramustine, doceta
A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813
✍ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor (G‐CSF) support in patients with hormone‐refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,

A phase I trial of ifosfamide and paclit
A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors
✍ Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ell 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Background: Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. ## Methods: Patients with refra